Staidson Biopharmaceuticals Hits Day Low at CNY 24.43 Amid Price Pressure

Staidson (Beijing) Biopharmaceuticals Co., Ltd. experienced a notable decline today, with the stock hitting an intraday low of CNY 24.43, reflecting a loss of 4.0% on June 1, 2026. This performance stands in contrast to the China Shanghai Composite, which decreased by only 0.27% during the same period. Over the past week, Staidson's stock has decreased by 1.47%, while its one-month performance shows a more significant drop of 10.42%. Year-to-date, the stock has declined by 9.41%, contrasting sharply with the Shanghai Composite's positive return of 2.24%. The company's financial metrics indicate challenges, including a negative net worth and a low return on capital employed (ROCE) of 0%. Staidson has reported negative results for six consecutive quarters, with net sales falling by 25.81% in the most recent quarter. Despite a three-year performance increase of 128.11%, the company faces ongoing difficulties in achieving sustainable growth, as evidenced by a long-term annual sales decline of 10.84%. As a large-cap player in the pharmaceuticals and biotechnology sector, Staidson's current market cap stands at CNY 12,734 million, but its financial health raises concerns among market observers.